Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:815363.
doi: 10.1155/2012/815363. Epub 2012 Jun 7.

Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom

Nianwen Shi  1 , Emily Durden, Amelito Torres, Zhun Cao, Michael Happich
Affiliations

Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom

Nianwen Shi et al. Depress Res Treat. 2012.

Abstract

Background. Knowledge about real-world use of duloxetine and venlafaxine XR to treat depression in the UK is limited. Aims. To identify predictors of duloxetine or venlafaxine XR initiation. Method. Adult depressed patients who initiated duloxetine or venlafaxine XR between January 1, 2006 and September 30, 2007 were identified in the UK's General Practice Research Database. Demographic and clinical predictors of treatment initiation with duloxetine and venlafaxine XR were identified using logistic regression. Results. Patients initiating duloxetine (n = 909) were 4 years older than venlafaxine XR recipients (n = 1286). Older age, preexisting unexplained pain, respiratory disease, and pre-period use of anticonvulsants, opioids, and antihyperlipidemics were associated with increased odds of initiating duloxetine compared to venlafaxine XR. Pre-period anxiety disorder was associated with decreased odds of receiving duloxetine. Conclusion. Initial treatment choice with duloxetine versus venlafaxine XR was primarily driven by patient-specific mental and medical health characteristics. General practitioners in the UK favor duloxetine over venlafaxine XR when pain conditions coexist with depression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient Selection.
Figure 2
Figure 2
Logistic regression predicting duloxetine or venlafaxine XR at index. (Venlafaxine XR served as the reference group in the model. Only predictors with statistical significance are displayed.)
See this image and copyright information in PMC

References

    1. Singleton N, Bumpstead R, O’Brien M, et al. Psychiatric Morbidity Among Adults Living in Private Households 2000. London, UK: The Stationery Office; 2001. - PubMed
    1. McCrone P, Dhanasiri S, Patel A, et al. Paying the Price: The Cost of Mental Health Care in England to 2026. London, UK: King’s Fund; 2008.
    1. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are ntidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? a meta-analysis of studies of newer agents. Biological Psychiatry. 2007;62(11):1217–1227. - PubMed
    1. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Journal of Clinical Psychopharmacology. 2007;27(6):672–676. - PubMed
    1. Kienke AS, Rosenbaum JF. Efficacy of venlafaxine in the treatment of severe depression. Depression and Anxiety. 2000;12(supplement 1):50–54. - PubMed

LinkOut - more resources